IX
Incannex Healthcare Limited
IXHL · NASDAQ
$3.59 -1.10% (-$0.04)
1M +10.47%
Market Cap $43.0M
P/E Ratio -
Div. Yield -
ROE 115.06%
Bulios Fair Price
$2.1
41.5% downside
Current Price
$3.59
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IXHL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
32 /100
Expensive P/S 499.45x
P/B 3.21x
P/E N/A
Growth
0 /100
Declining Rev. growth 52.15%
Book val. growth 28.08%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 186.05%
Net margin 54,517.40%
Op. margin 27,661.60%
Quality
0 /100
Poor ROIC 168.02%
ROE 115.06%
ROA 229.30%
Debt
69 /100
Low Debt/Equity 0.02x
Current ratio 2.86x
Int. coverage -78.51x
Stability
1 /100
Unstable Beta 2.83x
EPS volatility 616.48%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IXHL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Joel Bradley Latham
Employees
12
Headquarters
Sydney
Upcoming events
13 NOV
Earnings
Upcoming earnings report